ReviewDiabetology international2022
The forgotten type 2 diabetes mellitus medicine: rosiglitazone.
Review in Diabetology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Improving hepatic metabolic function with 3D iPSC-derived human hepatocytes.Cell biology and toxicology · 2026Article
- Pioglitazone plus (-)-epigallocatechin gallate: a novel approach to enhance osteogenic performance in aged bone marrow mesenchymal stem cells.FEBS open bio · 2026Article
- PPAR-γ Activation Alleviates Intestinal Dysfunction and Lactose Malabsorption in Experimental Food Allergy Rats.Nutrients · 2026Article
- Targeted lipid metabolism screening uncovers regulatory effects on the STING immune response in mevalonate, eicosanoid and fatty acid pathways.Frontiers in immunology · 2026Article
- Mutual solubilization of rosiglitazone and ibuprofen: Investigation and mechanistic insight.PloS one · 2026Article
- Interaction Between Microglial Lipid Droplet Metabolism and Immune Polarisation After Stroke: Mechanisms and Therapeutic Prospects.Cellular and molecular neurobiology · 2025Review
- Impact of Prenatal Dietary Soy on Cerebellar Neurodevelopment and Function in Experimental Fetal Alcohol Spectrum Disorder.Nutrients · 2025Article
- Dietary Soy Preserves Cognitive Function in Experimental Fetal Alcohol Spectrum Disorder: Role of Increased Signaling through Notch and Gonadotropin Releasing Hormone Networks.Journal of behavioral and brain science · 2025Article
- Natural flavonoids from herbs and nutraceuticals as ferroptosis inhibitors in central nervous system diseases: current preclinical evidence and future perspectives.Frontiers in pharmacology · 2025Review
- Harnessing Drug Repurposing to Combat Breast Cancer by Targeting Altered Metabolism and Epithelial-to-Mesenchymal Transition Pathways.ACS pharmacology & translational science · 2024Review
- Pioglitazone reverses alcohol-induced alterations in alveolar macrophage mitochondrial phenotype.Alcohol, clinical & experimental research · 2024Article
- Are treatment options used for adult-onset type 2 diabetes mellitus (equally) available and effective for children and adolescents?World journal of diabetes · 2024Review
- Harnessing peroxisome proliferator-activated receptor γ agonists to induce Heme Oxygenase-1: a promising approach for pulmonary inflammatory disorders.Cell communication and signaling : CCS · 2024Review
- Association between dietary soy prevention of fetal alcohol spectrum disorder and normalization of placental insulin and insulin-like growth factor signaling networks and downstream effector molecule expression.Gene & protein in disease · 2024Article
- Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Role of Gut Microbiota in High-Fat-Diet-Induced Diabetes: Lessons from Animal Models and Humans.Nutrients · 2023Review
- Targeting Adiponectin in Breast Cancer.Biomedicines · 2022Review
- Dietary Soy Prevents Alcohol-Mediated Neurocognitive Dysfunction and Associated Impairments in Brain Insulin Pathway Signaling in an Adolescent Rat Model.Biomolecules · 2022Article
- Molecular mechanism of benign biliary stricture inhibition by rosiglitazone-activated peroxisome proliferator-activated receptor gamma.Revista da Associacao Medica Brasileira (1992) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease prevalent in the world, and it is also one of the overall factors leading to overall morbidity and mortality. Throughout Asia, the proportion of people with T2DM and obesity has increased and this growth rate shows no signs of slowing down. Thiazolidinediones (TZDs) can specifically treat insulin resistance and improve metabolic syndrome, including rosiglitazone, troglitazone and pioglitazone, which are peroxisome proliferator-activated receptor (PPAR) agonists. These drugs have been shown to have better therapeutic effect and glycemic control, but also accompanied by a series of adverse reactions. Cardiovascular events are currently the most serious adverse events of rosiglitazone, which cardiovascular toxicity is higher than pioglitazone. Rosiglitazone has been restricted or even withdrawal from the market in most countries owing to concerns about its cardiovascular safety, while its beneficial effect on insulin resistance has been demonstrated. New data on rosiglitazone-mediated heart failure, myocardial infarction and fractures provide clinicians with prescriptions with fewer side effects to treat patients. Studies have shown that rosiglitazone is the most effective treatment in TZDs (in vivo study), not only hypoglycemic effect but with some additional effects, such as anti-inflammatory and anti-cancer capabilities, retinopathy (animal models) and ischemia-reperfusion injury protection effects, lipid regulation and blood pressure reduction, etc. Although rosiglitazone shows the highest risk of arrhythmia in diabetes management while has the capacity to reduce the risk of atrial fibrillation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.